Proton Radiotherapy May Be New Option for Peds Brain Tumor

This article originally appeared here.
Share this content:
Proton Radiotherapy May Be New Option for Peds Brain Tumor
Proton Radiotherapy May Be New Option for Peds Brain Tumor

MONDAY, Feb. 1, 2016 (HealthDay News) -- An open-label, phase 2 trial showed acceptable toxicity and survival rates for the use of proton radiotherapy in children with medulloblastoma. The findings were published online Jan. 29 in The Lancet Oncology.

Torunn I. Yock, M.D., of Massachusetts General Hospital in Boston, and colleagues enrolled 59 patients (aged 3 to 21 years) with medulloblastoma (standard risk, 39 participants; intermediate-risk, six; and high-risk, 14) in a nonrandomized, open-label, single-center, phase 2 trial to examine the toxicity profile of proton radiotherapy.

The researchers found that the median craniospinal irradiation dose was 23.4 Gy radiobiological equivalents (GyRBE) and the median boost dose was 54.0 GyRBE. At three years, grade 3 to 4 ototoxicity in both ears was observed in four (9 percent) of 45 evaluable patients; three (7 percent) developed grade 3 to 4 ototoxicity in one ear, but one later reverted to grade 2. The cumulative incidence of grade 3 to 4 hearing loss was 12 percent (95 percent confidence interval [CI], 4 to 25 percent) at three years and 16 percent (95 percent CI, 6 to 29 percent) at five years. Progression-free survival for all patients was 83 percent (95 percent CI, 71 to 90 percent) at three years and 80 percent (95 percent CI, 67 to 88 percent) at five years (in post-hoc analyses).

"Proton radiotherapy resulted in acceptable toxicity and had similar survival outcomes to those noted with conventional radiotherapy, suggesting that the use of the treatment may be an alternative to photon-based treatments," the authors write.

One author disclosed financial ties to ProCure.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

AAP: Congress Urged to Act to Prevent Firearm Deaths

AAP: Congress Urged to Act to Prevent Firearm ...

Following latest shooting, pediatricians join call for action to be taken to address firearm deaths, injury

Lung Cancer Incidence Higher for Young Women Than Young Men

Lung Cancer Incidence Higher for Young Women Than ...

Crossover in sex-specific rates among U.S. non-Hispanic whites born since 1965

E-Cigarette Flavoring Agent May Impair Airway Defense System

E-Cigarette Flavoring Agent May Impair Airway Defense System

Flavoring commonly used in e-cigarettes suppresses cilia beat frequency, lasting for 60 minutes

is free, fast, and customized just for you!

Already a member?

Sign In Now »